pharmaceutical-investing DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma
pharmaceutical-investing DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
pharmaceutical-investing DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
pharmaceutical-investing DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer
pharmaceutical-investing DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
pharmaceutical-investing CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead
pharmaceutical-investing DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market
pharmaceutical-investing DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083
pharmaceutical-investing DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
pharmaceutical-investing DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
pharmaceutical-investing DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
pharmaceutical-investing DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
pharmaceutical-investing DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
